中国临床药理学与治疗学2026，Vol.31Issue(4)：486-492,7.DOI:10.12092/j.issn.1009-2501.2026.04.007
双环醇联合血滞通胶囊对非酒精性脂肪性肝病的疗效研究
Efficacy of bicyclol combined with Xuezhitong capsules in the treat-ment of non-alcoholic fatty liver disease
摘要
Abstract
AIM:To systematically evaluate the comprehensive therapeutic efficacy and safety pro-file of the combination therapy of bicyclol tablets and Xuezhitong capsules in patients with non-alco-holic fatty liver disease(NAFLD).The research de-sign employed a prospective randomized con-trolled trial,allocating 160 NAFLD patients in a 1:1 ratio to two groups:the control group(n=80)re-ceived bicyclol tablets monotherapy,while the ex-perimental group(n=80)underwent a combination therapy of bicyclol tablets and Xuezhitong capsules,with a total treatment duration of 12 weeks.The study focused on comparing key liver function indi-cators,including alanine aminotransferase(ALT),as-partate aminotransferase(AST),γ-glutamyl transpeptidase(GGT),lipid profile parameters,in-cluding total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),liver fibro-sis progression markers,inflammatory mediator lev-els,and adverse event incidence rates between the two groups before and after treatment.RESULTS:After 12 weeks of systematic treatment,both groups demonstrated significant improvements in liver function indicators and lipid profile parame-ters(P<0.05).Notably,the experimental group showed superior improvements in key indicators compared to the control group:ALT levels de-creased by 41.8%(vs.26.4%in the control group),AST reduced by 33.9%(vs.21.8%),TC decreased by 14.4%(vs.9.6%),and TG showed a reduction of 25.2%(vs.14.3%)(P<0.05).Furthermore,the com-posite endpoint response rate in the experimental group was 88.8%,significantly higher than the con-trol group's 66.2%(P=0.001).Safety analysis re-vealed no statistically significant difference in ad-verse event incidence between the two groups(6.9%vs.10.6%,P=0.323).CONCLUSION:The com-bination therapy of bicyclol tablets and Xuezhitong capsules demonstrates superior clinical efficacy in NAFLD treatment.This innovative therapeutic strat-egy provides an optimal treatment option for the clinical management of NAFLD.关键词
非酒精性脂肪肝/双环醇片/血滞通胶囊/肝功能/血脂Key words
non-alcoholic fatty liver disease/bicy-clol/Xuezhitong capsule/liver function/lipids分类
医药卫生引用本文复制引用
金怡珊,江凤翔,谭姣容,朱明华..双环醇联合血滞通胶囊对非酒精性脂肪性肝病的疗效研究[J].中国临床药理学与治疗学,2026,31(4):486-492,7.基金项目
上海市普陀区卫生健康系统科技创新重点项目(ptkwws202502) （ptkwws202502）
